Claire Meek։ New Lancet Series on GLP-1 Receptor Agonists in Women’s Health
Claire Meek, Professor of Chemical Pathology and Diabetes in Pregnancy at the University of Leicester, shared a post on LinkedIn about papers she co-authored with colleagues published in The Lancet Obstetrics, Gynaecology, and Women’s Health:
“Women are among the biggest users of GLP-1 receptor agonists.
But where is the evidence designed specifically for women?
Today we publish a new Lancet Series on GLP-1 receptor agonists in women’s health, covering:
- Pregnancy, preconception and postnatal care
- Global access, safety and equity
- Menopause and healthy ageing
- The changing role of bariatric surgery in the GLP-1 era
Across all four papers, one message is consistent: women’s use of GLP-1 therapies has expanded faster than the evidence base supporting their use across key life stages.
We highlight what we know, what we do not know, and the research priorities needed to guide care for millions of women worldwide.
With many new incretin agents in the pipeline, we urgently need to address evidence gaps and structural access barriers to ensure women internationally have safe, healthy, and equitable care.
A huge thank you to an exceptional international team of authors and patient contributors who helped make this work.”
Title: Preconception, pregnancy, and postnatal use of GLP-1 receptor agonist-based therapies in women with type 1, type 2, or gestational diabetes: a systematic review, meta-analysis, and international expert consensus statement.
Authors: Sarah Dib, Matthew J Savage, Dawn Adams, Melanie J Davies, Rita Forde, Angela C Flynn, Paul W Franks, Alison Harte, Ritwika Mallik, Susan E Ozanne, Caroline Ovadia, Dimitris Papamargaritis, Rebecca M Reynolds, Prof Naveed Sattar, Sara G I Suliman, Prof Tricia Tan, Jovanna Tsoutsouki, Georgia Weston, Sara L White, Claire L Meek, on behalf of the GLP-1 Receptor Agonist Diabetes in Pregnancy Consensus Group.
You can read the Full Article in The Lancet Obstetrics, Gynaecology, and Women’s Health.

Title: Global barriers to GLP-1 receptor agonist treatment in women: access, safety, and equity
Authors: Claire L Meek, Ranjit Mohan Anjana, Nomathemba Chandiwana, Edith Wing Kar Chow, Denise R Franco, Bruno Halpern, Roberta Lamptey, Prof Ildiko Lingvay, Ronald Ching Wan Ma, Viswanathan Mohan, Sara G I Suliman, Paul W Franks.
You can read the Full Article in The Lancet Obstetrics, Gynaecology, and Women’s Health.

Stay informed with the latest updates in fertility and reproductive medicine on Fertility News.
-
Nov 18, 2026, 18:26Ritu Anand: We’ve Been Talking about Her Fertility – It’s Time to Talk about His
-
Nov 18, 2026, 18:20Sean Lauber: Is It Safe to Thaw and Rebiopsy an Embryo?
-
Nov 18, 2026, 18:14Arsiak Vartenian: 8 Years of Answering “Do You Have Kids?” Is a Long Time
-
Nov 18, 2026, 18:09Esther Eleboh: When the Same Protocol Produces Completely Different Embryo Outcomes
-
Nov 18, 2026, 18:05Resa Nabor: Having PCOS Doesn’t Make You Less of a Woman or Less Deserving of Love
-
Nov 18, 2026, 17:47Diana Kayal: Co-Chairing the 3rd International Conference on Gynecology and Women’s Health
-
Nov 18, 2026, 17:44Karthik Raj: Oocyte Quality Is Not Determined at Retrieval Alone
-
Nov 18, 2026, 17:41Tazeen Farhan: 10 Small Lifestyle Changes to Support Reproductive Health
-
Nov 18, 2026, 17:35Chanju Jung: Nature Paper Explores Base Editing in Human Embryos
